BNR
Burning Rock Biotech Limited NASDAQ$17.09
Mkt Cap $18.4M
52w Low $2.18
37.7% of range
52w High $41.72
50d MA $20.64
200d MA $16.63
P/E (TTM)
-0.3x
EV/EBITDA
6.6x
P/B
0.0x
Debt/Equity
0.1x
ROE
-10.3%
P/FCF
0.0x
RSI (14)
—
ATR (14)
—
Beta
1.60
50d MA
$20.64
200d MA
$16.63
Avg Volume
27.0K
About
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of ca…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -1.40 | -0.21 | +85.0% | 22.85 | -1.4% | -29.9% | -25.6% | -18.8% | -18.5% | -21.0% | -21.5% | — |
| Nov 20, 2025 | AMC | — | -0.26 | — | 15.53 | +0.1% | -8.2% | +6.9% | +25.2% | +37.4% | +39.0% | +50.6% | — |
| Sep 8, 2025 | AMC | — | -0.15 | — | 9.06 | -3.1% | +4.6% | -2.1% | -2.8% | -8.4% | -3.9% | -1.8% | — |
| Jun 6, 2025 | AMC | — | -0.17 | — | 2.90 | +3.4% | +4.1% | +11.7% | +3.8% | +39.0% | +32.1% | +22.8% | — |
| Mar 25, 2025 | AMC | -1.40 | -1.08 | +22.7% | 4.82 | -0.4% | -1.2% | -2.5% | -6.2% | -6.6% | -10.0% | -38.8% | — |
| Dec 3, 2024 | AMC | -1.41 | -0.50 | +64.5% | 6.10 | +6.2% | +13.6% | +13.9% | +17.4% | +15.1% | +10.0% | +21.1% | — |
| Aug 22, 2024 | AMC | -1.49 | -0.14 | +90.6% | 6.44 | -3.4% | -6.8% | -6.8% | -7.0% | -13.2% | -13.7% | -44.4% | — |
| May 29, 2024 | AMC | -1.52 | -0.16 | +89.5% | 7.55 | +1.9% | -5.3% | -5.3% | -0.8% | -0.8% | +1.2% | -14.6% | — |
| Mar 28, 2024 | AMC | — | -2.20 | — | 7.28 | +1.6% | -3.8% | -0.4% | +5.6% | -1.8% | -2.5% | +15.0% | — |
| Nov 30, 2023 | AMC | -1.81 | -2.30 | -27.2% | 8.30 | +0.0% | -0.1% | -0.8% | -3.6% | -7.2% | -4.8% | +16.7% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 14 | CICC | Maintains | Outperform → Outperform | — | $269.20 | $274.50 | +2.0% | +3.4% | +0.3% | +3.1% | -1.1% | +0.9% |
| Jul 13 | BofA Securities | Maintains | Buy → Buy | — | $260.30 | $264.80 | +1.7% | +8.9% | +7.6% | +13.8% | +8.7% | +9.2% |
| Jul 7 | Cowen & Co. | Maintains | Outperform → Outperform | — | $264.60 | $270.50 | +2.2% | +2.0% | +0.8% | -1.4% | -1.6% | +7.1% |
Data updated apr 26, 2026 9:55am
· Source: massive.com